Sign In
Buy SITC
$4.88
-0.0500 (-1.01%)
At Close: Jun 03, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in C
Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy pla
Allianz Asset Management GmbH Sells 49,817 Shares of Site Centers Corp. $SITC
03:56am, Wednesday, 29'th Oct 2025
Allianz Asset Management GmbH lowered its holdings in shares of Site Centers Corp. (NYSE: SITC) by 61.0% during the second quarter, according to its most recent filing with the Securities and Exchange
SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025
04:05pm, Monday, 27'th Oct 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025.
Site Centers Corp. (NYSE:SITC) Receives Consensus Recommendation of “Hold” from Brokerages
01:53am, Sunday, 26'th Oct 2025
Site Centers Corp. (NYSE: SITC - Get Free Report) has received an average recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat.com reports. One analy
SITE Centers Announces Special Common Stock Distribution
06:50am, Tuesday, 21'st Oct 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers, today announced a special cash distribution on its common shares of $1.00 per common share pay
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispeci
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
07:00am, Monday, 06'th Oct 2025
BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
09:05am, Friday, 03'rd Oct 2025
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
09:05am, Friday, 03'rd Oct 2025
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolyt
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
09:00am, Friday, 03'rd Oct 2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
09:00am, Friday, 03'rd Oct 2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
07:30am, Friday, 03'rd Oct 2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-st
